Intellectual Property

AmProtein has revolutionized protein manufacture through use of two important proprietary systems:

  1. The discovery of a DNA physical structure-based expression mechanism common to eukaryotic cells, known as 'the GC-rich method.'
  2. Non-sparging, novel O2 transfer method, resulting in commercialization of single-use, plastic bag-based bioreactors and paper carrier-based perfusion system.

By taking advantage of the above discoveries, AmProtein has developed dual-domain protein therapeutics with improved efficacies and longer half-lives for unmet medical needs.

AmProtein owns all of the below published patents:

AmProtein also owns five unpublished priority patents.

AmProtein is interested in transfer and out-licensing of these technologies and patents.